Viyash Scientific Limited - Asset Resilience Ratio
Viyash Scientific Limited (SEQUENT) has an Asset Resilience Ratio of 0.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see Viyash Scientific Limited (SEQUENT) total assets.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Viyash Scientific Limited's Asset Resilience Ratio has changed over time. Read SEQUENT current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Viyash Scientific Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See Viyash Scientific Limited defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs14.50 Million | 0.08% |
| Total Liquid Assets | Rs14.50 Million | 0.08% |
Asset Resilience Insights
- Limited Liquidity: Viyash Scientific Limited maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Viyash Scientific Limited Industry Peers by Asset Resilience Ratio
Compare Viyash Scientific Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Livzon Pharmaceutical Group Inc
SHE:000513 |
Drug Manufacturers - Specialty & Generic | 2.93% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
Annual Asset Resilience Ratio for Viyash Scientific Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Viyash Scientific Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.03% | Rs4.18 Million ≈ $45.21K |
Rs16.02 Billion ≈ $173.24 Million |
-0.23pp |
| 2024-03-31 | 0.26% | Rs39.75 Million ≈ $429.88K |
Rs15.40 Billion ≈ $166.59 Million |
+0.26pp |
| 2023-03-31 | 0.00% | Rs460.00K ≈ $4.97K |
Rs15.29 Billion ≈ $165.37 Million |
-0.11pp |
| 2022-03-31 | 0.11% | Rs16.25 Million ≈ $175.74K |
Rs14.51 Billion ≈ $156.92 Million |
-0.32pp |
| 2021-03-31 | 0.43% | Rs59.59 Million ≈ $644.44K |
Rs13.93 Billion ≈ $150.60 Million |
-2.32pp |
| 2020-03-31 | 2.75% | Rs401.79 Million ≈ $4.35 Million |
Rs14.63 Billion ≈ $158.18 Million |
+2.71pp |
| 2019-03-31 | 0.03% | Rs4.70 Million ≈ $50.83K |
Rs13.88 Billion ≈ $150.09 Million |
-1.26pp |
| 2018-03-31 | 1.29% | Rs173.45 Million ≈ $1.88 Million |
Rs13.43 Billion ≈ $145.21 Million |
-2.14pp |
| 2017-03-31 | 3.43% | Rs653.76 Million ≈ $7.07 Million |
Rs19.05 Billion ≈ $205.98 Million |
-0.95pp |
| 2016-03-31 | 4.38% | Rs669.78 Million ≈ $7.24 Million |
Rs15.28 Billion ≈ $165.26 Million |
+4.32pp |
| 2015-03-31 | 0.06% | Rs5.81 Million ≈ $62.83K |
Rs9.08 Billion ≈ $98.16 Million |
+0.05pp |
| 2014-03-31 | 0.01% | Rs770.00K ≈ $8.33K |
Rs6.23 Billion ≈ $67.34 Million |
-0.02pp |
| 2013-03-31 | 0.03% | Rs1.77 Million ≈ $19.14K |
Rs5.86 Billion ≈ $63.40 Million |
-0.02pp |
| 2012-03-31 | 0.05% | Rs2.77 Million ≈ $29.96K |
Rs5.47 Billion ≈ $59.19 Million |
-0.18pp |
| 2011-03-31 | 0.23% | Rs10.25 Million ≈ $110.85K |
Rs4.50 Billion ≈ $48.65 Million |
-4.31pp |
| 2006-03-31 | 4.54% | Rs12.46 Million ≈ $134.71K |
Rs274.60 Million ≈ $2.97 Million |
-- |
About Viyash Scientific Limited
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was former… Read more